Japanese drugmaker Maruho has entered into an exclusive license agreement to develop and commercialize Alchemedicine's aldehyde dehydrogenase 2 (ALDH2) activator following Maruho's exercise of the option right included in the exclusive negotiation and evaluation agreement that had already been executed between the companies.
Under the terms of the license agreement, Alchemedicine grants Maruho exclusive, worldwide rights to develop, manufacture, and commercialize the compound in designated disease areas. Maruho will pay Alchemedicine an upfront payment and potential development and commercial milestone payments, as well as tiered royalties based on sales. The license agreement includes backup compounds possessed by Alchemedicine that selectively activate ALDH2.
ALDH2 is a mitochondrial enzyme, which is generally known to detoxify acetaldehyde, a toxic substance that is produced after alcohol consumption. As ALDH2 also acts on various substances other than acetaldehyde, the compound is expected to have potential for use in a wide range of indications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze